Atlas Trials

HER2+ Metastatic Breast Cancer (MBC)

2 clinical trials · Condition

Sort:Newest firstOldest first

◉ Watch HER2+ Metastatic Breast Cancer (MBC)

RecordFirmDate
A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting (NCT01808573)Puma Biotechnology, Inc.2013-03-29

Track HER2+ Metastatic Breast Cancer (MBC) automatically

Every clearance here is in the API, with alerts when new ones post.